Immunome (IMNM) Cash & Equivalents (2019 - 2026)

Immunome has reported Cash & Equivalents for 8 years, with the latest figure at $582.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 126.19% year-over-year to $582.7 million; the trailing twelve-month figure through Mar 2026 stood at $582.7 million (up 126.19% YoY), and the FY2025 full-year result was $653.5 million, up 355.86% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $582.7 million, down from $653.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $653.5 million in Q4 2025, with the low at $20.3 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $178.9 million across 5 years, with a median of $143.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 58.72% — and 2024, when it surged 507.16%.
• Immunome's Cash & Equivalents stood at $20.3 million in 2022, then surged by 385.55% to $98.7 million in 2023, then jumped by 45.27% to $143.4 million in 2024, then jumped by 355.86% to $653.5 million in 2025, then slipped by 10.83% to $582.7 million in 2026.
• The last three Cash & Equivalents figures came in at $582.7 million (Q1 2026), $653.5 million (Q4 2025), and $272.6 million (Q3 2025), per Business Quant data.